CN1785318A - Chinese medicinal preparation for treating urethra infection - Google Patents
Chinese medicinal preparation for treating urethra infection Download PDFInfo
- Publication number
- CN1785318A CN1785318A CN 200510095297 CN200510095297A CN1785318A CN 1785318 A CN1785318 A CN 1785318A CN 200510095297 CN200510095297 CN 200510095297 CN 200510095297 A CN200510095297 A CN 200510095297A CN 1785318 A CN1785318 A CN 1785318A
- Authority
- CN
- China
- Prior art keywords
- grams
- herba
- present
- group
- urinary tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine in the form of particles for treating urethral infection is prepared from common sage herb, plantain herb, threeflower bluebeard, and to kyo violet herb.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, particularly a kind of Chinese medicine preparation for the treatment of urinary tract infection.
Background technology
Urinary tract infection (Urinary tract infection, be called for short UTI) be meant with or without the urinary tract inflammation that a large amount of pathogenic microorganism of clinical symptoms are grown in urine, bred and cause, mainly show as upper urinary tract infection (acute cystitis, acute urethra symptom group), lower urinary tract infection (acute and chronic pyelonephritis), fungoid urethritis and silent inflammation etc. clinically.
Urinary tract infection not only endangers greatly, and the sickness rate height, belongs to women's frequently-occurring disease, commonly encountered diseases.In China, its sickness rate is 0.91%, and M-F is roughly 1: 10, and as seen its harm is big.
Before the present invention, the treatment urinary tract infection mainly is with antibiosis control infection usually.Use antibiotic defective obvious: the one, abuse of antibiotics causes untoward reaction and toxicity, does not meet the relevant antibacterials clinical practice guideline of country; The 2nd, therapeutic effect is undesirable, relapse rate and to be converted into the ratio of chronic renal failure high; The 3rd, antibacterial therapy urinary tract infection therapy is more single, must carry out Comprehensive Treatment in conjunction with diuresis, enhancing human body immunity power etc., increases and drug interaction and promptly produce medical fee behind the drug combination.
It is at present also indeterminate to be familiar with urinary tract infection mechanism from the theory of Chinese medical science system, so effective prescription of treatment by Chinese herbs urinary tract infection is few.The formulation components of Chinese medicine is many at present, composition is complicated, and effect is undesirable.
Summary of the invention
Purpose of the present invention just is to overcome above-mentioned defective, develops a kind of Chinese medicine preparation of simple and effective treatment urinary tract infection.
Technical scheme of the present invention is:
The Chinese medicine preparation of treatment urinary tract infection, its major technique is characterised in that by Herba Salviae Plebeiae, Herba Plantaginis, Serissa foetida, Herba Violae to be formed, and its content is Herba Salviae Plebeiae 372～504 grams, Herba Plantaginis 372～504 grams, Serissa foetida 372～504 grams, Herba Violae 186～252 grams.
Advantage of the present invention and effect are that Herba Salviae Plebeiae has the effect of heat-clearing and toxic substances removing, inducing diuresis to remove edema, cooling blood for hemostasis, Herba Plantaginis has the effect of clearing away heat and promoting diuresis, Serissa foetida has the effect of dispelling wind to relieve the exterior syndrome, clearing hot and promoting blood, relaxing muscles and tendons and activating QI and blood in the collateral, Herba Violae has the effect of heat-clearing and toxic substances removing, removing heat from blood detumescence, four Chinese medicine merges can produce synergism, the treatment urinary tract infection obtains good stable effect.And the present invention selects for use Chinese prescription few, avirulence or have only slight side effect.
Effect of the present invention and effect are described continuing in the specific embodiment below.
The specific embodiment
Embodiment 1:
Get Herba Salviae Plebeiae 438 gram, Herba Plantaginis 438 grams, Serissa foetida 438 grams, Herba Violae 219 grams, an amount of with sucrose, dextrin.The above-mentioned medical material that meets the pharmacopeia quality standard decocts, concentrates, extractum (assay, relative density are measured), and granulation, oven dry, granulate are packaged to granule 1000 grams.Also can make other preparations of patient's acceptable.Wherein, high effective liquid chromatography for measuring is pressed dry product and is calculated, and every gram contains homoplantaginin (C
22H
22O
11) must not be lower than 0.08mg.
Instructions of taking: boiled water is taken after mixing it with water, each 15 grams, 3 times on the one.
Said preparation has antibiotic, diuresis dual function, especially to chronic urinary tract system infected patient, it is slight to take side effect for a long time, and curative effect is reliable.
Embodiment 2:
Get Herba Salviae Plebeiae 420 gram, Herba Plantaginis 420 grams, Serissa foetida 420 grams, Herba Violae 210 grams, an amount of with sucrose, dextrin.Surplus with embodiment 1.
As follows to pharmacodynamics test of the present invention:
One, in-vitro antibacterial experiment:
The present invention is to reference culture staphylococcus aureus, micrococcus luteus, and clinical isolates strain staphylococcus aureus, bacillus pyocyaneus, staphylococcus hominis, staphylococcus epidermidis, the false monospore bacillus of Bulbus Allii Cepae, citric acid enterobacteria, Bacillus proteus have stronger bacteriostasis.
Two, antibacterial experiment in the mice body:
When dosage of the present invention is 50.4g/kg, the death of Bacillus proteus infecting mouse there is obvious protective effect.
Get 200 of 19-22g Kunming mouses, be divided into 10 groups at random, 20 every group, (1), (2) are the normal saline group, normal saline 20ml/kg; (3), (4) be the SHUANGHUANLIAN group, SHUANGHUANGLIAN FENZHENJI 3.5g/kg; (5), (6) be granule small dose group of the present invention, dosage is 12.6g/kg; (7), (8) be dosage group in the granule of the present invention, dosage is 25.2g/kg; (9), (10) be the heavy dose of group of granule of the present invention, dosage is 50.4g/kg; Each group is all used the 20ml/kg gastric infusion, every day 1 time, continuous 3 days.1h after the last administration, lumbar injection escherichia coli culture fluid (1,3,5,7,9 group) and Bacillus proteus culture fluid (2,4,6,8,10 groups), 0.5ml/ only observe 72h animal dead situation.
Evidence when dosage of the present invention is 50.4g/kg, has obvious protective effect to the death of Bacillus proteus infecting mouse.
Three, antiinflammatory action
1. mice caused by dimethylbenzene xylene auricle edema test
Get 50 of Kunming mouses, body weight 18-21g, year is divided into 5 groups at random, and 10 every group, ♀ ♂ half and half (snow litchi granule is that the present invention is called for short).
(1) the normal control group gives the equivalent normal saline;
(2) Dexamethasone group 5mg/kg;
(3) granule I group 12.6g/kg of the present invention;
(4) granule II group 25.2g/kg of the present invention;
(5) granule III group 50.4g/kg of the present invention;
Each treated animal ig administration, administration capacity 0.2ml/10g Mus is heavy, and 1 time/d, continuous 5d.1h after the last administration is applied to auricle two sides, a mice left side with 30 μ l dimethylbenzene and causes inflammation, and auris dextra is contrast, cause scorching back 45min and put to death mice, lay left and right sides auricle, weigh with the card punch of diameter 8mm,, calculate swelling and suppress percentage rate as the swelling degree with left and right sides auricle weight difference.
Evidence, the present invention can significantly reduce mice caused by dimethylbenzene xylene ease auricle swelling degree when 11.6g/kg, 34.6g/kg, 69.6g/kg.
2. mouse skin capillary permeability test
Get 50 of Kunming mouses, body weight 18-21g is divided into 5 groups at random, and 10 every group, ♀ ♂ half and half.
(1) the normal control group gives the equivalent normal saline;
(2) Dexamethasone group 5mg/kg;
(3) granule I group 12.6g/kg of the present invention;
(4) granule II group 25.2g/kg of the present invention;
(5) granule III group 50.4g/kg of the present invention;
Each treated animal ig administration, administration capacity 0.2ml/10g Mus is heavy, and 1 time/d, continuous 5d.1h after the last administration, mouse tail iv 0.5% azovan blue solution 0.2ml/10g Mus is heavy, drip dimethylbenzene 40 μ 1 in the unhairing abdominal part immediately, put to death mice behind the 15min, take off homalographic indigo plant with the card punch of diameter 12mm and dye skin, shred to put into and fill 2ml acetone: the test tube of water (7: 3) solution soaks, and places the centrifugal 5min of 3000rpm behind the 20h, get supernatant in the 590nm colorimetric, judge the mouse skin capillary permeability with light absorption value (O.D).
Evidence can reduce the mouse skin capillary permeability very significantly.
Four, analgesic activity
Clear paste of the present invention can obviously reduce mice and turn round number of times when 11.6g/kg dosage, and weak analgesic activity is arranged; When 34.6g/kg and 69.6g/kg dosage, turn round number of times and more reduce, strong analgesic activity is arranged.Three kinds of dosage all can make hot plate method mice pain threshold significantly improve.
Five, heat clearing away test
Clear paste of the present invention is when 12.6g/kg, 25.0g/kg dosage, and antler glue is caused rat fever obvious heat clearing away effect, slower during beginning.When 3.6g/kg, 7.2g/kg and 14.4g/kg dosage, TAB is caused fever in rabbits tangible heat clearing away effect, and the time started is very fast.
Six, diuresis test
Get 50 of ♂ rats, body weight 180-200g is divided into 5 groups at random, 10 every group.
(1) the normal control group gives the equivalent normal saline;
(2) aspirin group 0.1g/kg;
(3) granule I group 6.3g/kg of the present invention;
(4) granule II group 12.6g/kg of the present invention;
(5) granule III group 25.2g/kg of the present invention;
Each treated animal ig administration, administration capacity 1ml/100mg Mus is heavy, and 1 time/d, continuous 3d.Animal fasting 18h before the experiment, the water load is irritated stomach, per hour 1 time totally 2 times with 38 ℃ of normal saline 25ml/kg.Gently press the thing lower abdomen during experiment beginning and drain surplus urine.Immediately rat is put into metabolic cage after the last administration, collect each treated animal urine amount totally 3 times behind the 1h, each 60min.
Evidence when above-mentioned three dosage, can make rat have obviously or very significantly increase in the urine amounts of different periods.
As follows to the toxicology test that the present invention carries out:
One, acute toxicity test
Get 50 of Kunming mouses, body weight 19-22g is divided into 5 groups at random, and 10 every group, ♀ ♂ half and half.Give a dosage, be respectively: 52.2g/kg, 61.4g/kg, 72.3g/kg, 85.0g/kg, 100.0g/kg for every group.Behind fasting (the can't help water) 12h, each group weighs gastric infusion 1 time by above-mentioned dosage 0.4ml/10g Mus respectively before testing, and observes for 1 week behind the filling stomach, and record is tried mice activity, behavior and death condition, and the back execution of 1 week performs an autopsy on sb.
Evidence: irritate no remarkable toxic reaction behind the stomach, also do not have death in the week, and this dosage is 138 times of clinical 1 day oral dose (dose,equivalents 12.5 times).
Two, long term toxicity test
Granule low dose group of the present invention: 12.5g/kg, 10.7 times of clinical dosage, 2 times of dose,equivalent; Dosage group: 31.3g/kg in the granule of the present invention, 27 times of clinical dosage, 5 times of dose,equivalent; Granule high dose group of the present invention: 62.6g/kg, 54 times of clinical dosage, 10 times of dose,equivalent.Normal control group: give the equivalent normal saline.
3 dosage groups of granule of the present invention, isometric(al) is isoconcentration not, and give respectively by above-mentioned dosage every day, administration volume 10ml/kg body weight, 1 gastric infusion, successive administration 6 months.Each group is cutd open 10 animals extremely in the time of 3 months, checks every index comprehensively.Cut open half of killing remaining animal in the time of 6 months, do every detection, second half drug withdrawal continues to observe remaking body weight, food ration, routine urinalysis, routine blood test, blood biochemical, the every detection of organ coefficient 2 weeks.
Rat oral gavage 3 months are given in evidence continuously, and ordinary circumstance is good as a result, weight increase, and every indexs such as food ration, routine urinalysis, routine blood test, blood biochemical are all normal; Histological examination shows, internal organs such as the present invention is dirty to rat heart, liver, lungs, gland, kidney, adrenal gland, thymus, ovary, testis do not have any histology's influence.
Clinical application result of the present invention is as follows:
The present invention comprises cystitis, prostatitis, chronic pyelonephritis (symptom is seen frequent micturition, urgent micturition, dysurea, waist abdominal distention and pain etc.) to damp invasion of lower energizer or double damp-heat in lower-JIAO, pyretic stranguria oliguria with reddish urine, the puckery pain of pouring drop of suffering from a deficiency of the kidney and levying, and curative effect is particularly remarkable.Its cure rate 75%, total effective rate are 90%.Short treating period, transference cure are fast.
Kidney tonifying tonify deficiency of the present invention, invigorating blood circulation dysentery, the diarrhea of heat type that disappears urine help pathogenic bacteria and toxin excretes by urine, regulate body function, the human body immunity improving ability; Antibiotic active ingredient of the present invention is rushed down with urine row through kidney, more helps the antibacterial of urinary tract pathogenic bacteria and sterilization.Do not see obvious toxicity.
Composing prescription preparation stability experiment result of the present invention is as follows:
Influence factor's test
1. strong illumination test
Place the illuminance of Lx to shine 10 days in the sample of removing outer package, respectively the 1st, 3,5,10 day every index such as sampling and measuring content.
2. hot test
Place airtight vessel to place 10 days in the sample of removing outer package, respectively the 1st, 3,5,10 day every index such as sampling and measuring content respectively at 40 ℃, 60 ℃, 80 ℃ constant temperature ovens.
3. high wet test
Place airtight vessel to place 10 days under respectively at the condition of relative humidity 75%, 92.5% in the sample of removing outer package, respectively the 1st, 3,5,10 day every index such as sampling and measuring content at 25 ℃.
The result shows, stable in properties of the present invention.
Claims (5)
1. the Chinese medicine preparation of treatment urinary tract infection is characterized in that being made up of Herba Salviae Plebeiae, Herba Plantaginis, Serissa foetida, Herba Violae, and its content is Herba Salviae Plebeiae 372～504 grams, Herba Plantaginis 372～504 grams, Serissa foetida 372～504 grams, Herba Violae 186～252 grams.
2. the Chinese medicine preparation of treatment urinary tract infection according to claim 1 is characterized in that adding appropriate amount of auxiliary materials sucrose, dextrin.
3. the Chinese medicine preparation of treatment urinary tract infection according to claim 1 is characterized in that Herba Salviae Plebeiae 438 grams, Herba Plantaginis 438 grams, Serissa foetida 438 grams, Herba Violae 219 grams.
4. the Chinese medicine preparation of treatment urinary tract infection according to claim 1 is characterized in that Herba Salviae Plebeiae 420 grams, Herba Plantaginis 420 grams, Serissa foetida 420 grams, Herba Violae 210 grams.
5. the Chinese medicine preparation of treatment urinary tract infection according to claim 1 is characterized in that every gram contains homoplantaginin (C
22H
22O
11) must not be lower than 0.08mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100952975A CN100352474C (en) | 2005-11-08 | 2005-11-08 | Chinese medicinal preparation for treating urethra infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100952975A CN100352474C (en) | 2005-11-08 | 2005-11-08 | Chinese medicinal preparation for treating urethra infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785318A true CN1785318A (en) | 2006-06-14 |
| CN100352474C CN100352474C (en) | 2007-12-05 |
Family
ID=36782986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100952975A Active CN100352474C (en) | 2005-11-08 | 2005-11-08 | Chinese medicinal preparation for treating urethra infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100352474C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138581B (en) * | 2007-09-13 | 2010-12-15 | 贵阳春科药业技术研发有限公司 | Traditional chinese medicine preparation for treating urinary system infection contamination and method of preparing the same |
| CN103285175A (en) * | 2013-06-19 | 2013-09-11 | 南京大学医学院附属鼓楼医院 | Serissa japonica and Common Sage Herb composition active components and preparation thereof |
| CN105031177A (en) * | 2015-07-09 | 2015-11-11 | 青岛华仁技术孵化器有限公司 | Traditional Chinese medicine composition for treating urinary tract infection and preparation method of traditional Chinese medicine composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046416C (en) * | 1993-09-25 | 1999-11-17 | 王绍和 | Chyluria granule |
| CN1160544A (en) * | 1996-03-27 | 1997-10-01 | 吴锡信 | Chinese herbal medicine liniment for the prevention and cure of venereal disease |
-
2005
- 2005-11-08 CN CNB2005100952975A patent/CN100352474C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138581B (en) * | 2007-09-13 | 2010-12-15 | 贵阳春科药业技术研发有限公司 | Traditional chinese medicine preparation for treating urinary system infection contamination and method of preparing the same |
| CN103285175A (en) * | 2013-06-19 | 2013-09-11 | 南京大学医学院附属鼓楼医院 | Serissa japonica and Common Sage Herb composition active components and preparation thereof |
| CN103285175B (en) * | 2013-06-19 | 2015-01-21 | 南京大学医学院附属鼓楼医院 | Serissa japonica and Common Sage Herb composition active components and preparation thereof |
| CN105031177A (en) * | 2015-07-09 | 2015-11-11 | 青岛华仁技术孵化器有限公司 | Traditional Chinese medicine composition for treating urinary tract infection and preparation method of traditional Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100352474C (en) | 2007-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1927281A (en) | Chinese herbal medicine slow release agent for preventing and treating rabbit and chicken coccidiosis and preparing method thereof | |
| CN102225127B (en) | Traditional Chinese medicine composite for treating mastitis of dairy cattle | |
| CN100352474C (en) | Chinese medicinal preparation for treating urethra infection | |
| CN1192787C (en) | Chinese medicine for treating ulcerative colitis and its preparing process | |
| CN103181958A (en) | Chinese herbal medicine perfusate for treating endometritis of cow and preparation method thereof | |
| CN101934032B (en) | Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof | |
| CN101342243B (en) | Traditional Chinese medicine transdermal ointment for treating mastadenitis of cow and preparation method thereof | |
| CN101829182B (en) | Medicament for treating prostatic diseases | |
| CN1600333A (en) | Painkiller | |
| CN1386536A (en) | Medicine for treating dermatopathy | |
| CN102743667A (en) | Quick-acting detoxifcation herpes zoster eliminating ointment | |
| CN101036701A (en) | Chinese traditional medicine lotion | |
| CN1634361A (en) | Traditional Chinese medicine powder for treating mastitis of dairy cattle | |
| CN1112003A (en) | Health sticker for lactation | |
| CN101804135A (en) | Compound combined drug for treating poultry coccidiosis and preparation method thereof | |
| CN101209315A (en) | Chinese medicinal injection with antimicrobial and anti-inflammation, milk-smoothing and mass-dissipating efficacy | |
| CN101461850B (en) | Application of Chinese medicinal composition in preparing medicament for treating acne | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN101396427A (en) | Traditional Chinese medicine oral liquid for treating poultry virus hepatitis and hepatic injury | |
| CN1836694A (en) | Medicine composition for treating cardiovascular diseases and preparation method thereof | |
| CN1943632A (en) | A kind of medicine for treating infant cold and its preparing method | |
| AU2021105905A4 (en) | A Pharmaceutical Composition for Treating Diarrhea Of Piglet And Its Preparation Method | |
| CN118576689B (en) | Traditional Chinese medicine composition for treating pelvic inflammatory disease and preparation method and application thereof | |
| CN1644206A (en) | Medicine for treating tinea containing biological alkaline salt and preparation thereof | |
| CN102755503B (en) | Traditional Chinese medicine composition for treating skin trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HU NAN QIU ZEYOU PATENT STRATEGIC PLANNING CO., LT Free format text: FORMER OWNER: QIU ZEYOU Effective date: 20101028 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410011 28/F, SHUNTIANCHENG, NO.59, SECTION 2 OF FURONG MIDDLE ROAD, CHANGSHA CITY, HU NAN PROVINCE TO: 410205 JUXING INDUSTRY BASE, NO.8, LUJING ROAD, CHANGSHA HIGH-TECH. DEVELOPMENT ZONE, YUELU DISTRICT, CHANGSHA CITY, HU NAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101108 Address after: 225321 No. 1 Jiangnan Road, Taizhou high port district Patentee after: Yangtze River Pharmaceutical Co., Ltd. Address before: 210008 Zhongshan Road, Jiangsu, No. 321, Patentee before: Gulou Hospital Attached to Medical College of Nanjing Univ. |